Asper Immunogenetics

Published 11/04/2023

Asper Immunogenetics

Antibody Deficiency (a- and hypogammaglobulinemia) UPDATED
Autoimmunity and Lymphoproliferation
Hyper IgE Syndrome
Combined immunodeficiency UPDATED
Chronic granulomatous disease
Primary ciliary dyskinesia
Hereditary angioedema
Hereditary autoinflammatory syndrome
Genetic susceptibility to mycobacterial diseases
Genetic susceptibility to fungal infections/candidosis
Genetic susceptibility to viral infections (including herpes)
Whole Exome Sequencing
Familial mutation testing

List of diseases covered by Metabolic Myopathy and Rhabdomyolysis NGS panel

Published 18/06/2022

List of diseases covered by
Metabolic Myopathy and Rhabdomyolysis NGS panel

Gene Condition
ABHD5 Chanarin-Dorfman syndrome
ACAD9 Mitochondrial complex I deficiency due to ACAD9 deficiency
ACADM Acyl-CoA dehydrogenase, medium chain, deficiency of
ACADVL VLCAD deficiency
AGL Glycogen storage disease IIIa
ALDOA Glycogen storage disease XII
AMPD1 Myopathy due to myoadenylate deaminase deficiency
CAV3 Muscular dystrophy, limb-girdle, type IC;
Cardiomyopathy, familial hypertrophic;
Creatine phosphokinase, elevated serum;
Long QT syndrome 9; Myopathy, distal, Tateyama type;
Rippling muscle disease
CPT2 CPT II deficiency, infantile; CPT II deficiency, lethal neonatal;
CPT II deficiency, myopathic, stress-induced
ENO3 Glycogen storage disease XIII
ETFA Glutaric acidemia IIA
ETFB Glutaric acidemia IIB
ETFDH Glutaric acidemia IIC
FLAD1 Lipid storage myopathy due to flavin adenine dinucleotide synthetase deficiency
GAA Glycogen storage disease II
GBE1 Glycogen storage disease IV; Polyglucosan body disease, adult form
GYG1 Glycogen storage disease XV; Polyglucosan body myopathy 2
GYS1 Glycogen storage disease 0, muscle
HADHA LCHAD deficiency; Trifunctional protein deficiency
HADHB Trifunctional protein deficiency
ISCU Myopathy with lactic acidosis, hereditary
LDHA Glycogen storage disease XI
LPIN1 Myoglobinuria, acute recurrent, autosomal recessive
OPA1 Mitochondrial DNA depletion syndrome 14;
Behr syndrome; Optic atrophy 1; Optic atrophy plus syndrome
OPA3 3-methylglutaconic aciduria, type III; Optic atrophy 3 with cataract
PFKM Glycogen storage disease VII
PGAM2 Glycogen storage disease X
PGK1 Phosphoglycerate kinase 1 deficiency
PGM1 Congenital disorder of glycosylation, type It
PHKA1 Muscle glycogenosis
PNPLA2 Neutral lipid storage disease with myopathy
PRKAG2 Cardiomyopathy, hypertrophic 6;
Glycogen storage disease of heart, lethal congenital;
Wolff-Parkinson-White syndrome
POLG Mitochondrial DNA depletion syndrome 4A;
Mitochondrial DNA depletion syndrome 4B;
Mitochondrial recessive ataxia syndrome;
Progressive external ophthalmoplegia, autosomal dominant 1;
Progressive external ophthalmoplegia, autosomal recessive 1
POLG2 Progressive external ophthalmoplegia
with mitochondrial DNA deletions, autosomal dominant 4
PYGM McArdle disease
RRM2B Mitochondrial DNA depletion syndrome 8A;
Progressive external ophthalmoplegia
with mitochondrial DNA deletions, autosomal dominant 5
RYR1 Minicore myopathy with external ophthalmoplegia;
Central core disease; Malignant hyperthermia, susceptibility to, 1
SCN4A Hyperkalemic periodic paralysis, type 2;
Hypokalemic periodic paralysis, type 2; Myasthenic syndrome, congenital, 16;
Myotonia congenita, atypical, acetazolamide-responsive;
Paramyotonia congenita
SLC22A5 Carnitine deficiency, systemic primary
SLC25A20 Carnitine-acylcarnitine translocase deficiency
SUCLA2 Mitochondrial DNA depletion syndrome 5
SLC52A1 Riboflavin deficiency
SLC52A2 Brown-Vialetto-Van Laere syndrome 2
SLC52A3 Brown-Vialetto-Van Laere syndrome 1
TAZ Barth syndrome
TK2 Progressive external ophthalmoplegia
with mitochondrial DNA deletions, autosomal recessive 3;
TWNK Perrault syndrome 5; Mitochondrial DNA depletion syndrome 7;
Progressive external ophthalmoplegia
with mitochondrial DNA deletions, autosomal dominant 3
TYMP Mitochondrial DNA depletion syndrome 1 (MNGIE type)

Asper Oncogenetics news

Published 22/09/2021

New panel specifically targeting mutations in 25 genes implicated in renal cancer is now available. In addition, we have added genes to the melanoma and the prostate cancer gene sets. Visit asper-oncogenetics to learn more!

Hyperinsulinism NGS panel

Published 10/09/2021

Hyperinsulinism NGS panel

Genes
(full
coding
region):		 ABCC8, GCK, GLUD1, HADH, HK1, HNF1A, HNF4A, INSR, KCNJ11, PMM2, SLC16A1, UCP2

List of diseases covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

List of diseases covered by Renal Cancer NGS panel

Published 09/09/2021

List of diseases covered by
Renal Cancer NGS panel

Gene Condition
BAP1 Tumor predisposition syndrome
CDC73 Hyperparathyroidism, familial primary; Hyperparathyroidism-jaw tumor syndrome;
Parathyroid carcinoma
CDKN1C Beckwith-Wiedemann syndrome; IMAGE syndrome
DICER1 Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors;
Pleuropulmonary blastoma;
Rhabdomyosarcoma, embryonal, 2
DIS3L2 Perlman syndrome
EPCAM Colorectal cancer, hereditary nonpolyposis, type 8;
Diarrhea 5, with tufting enteropathy, congenital
FH Leiomyomatosis and renal cell cancer; Fumarase deficiency
FLCN Birt-Hogg-Dube syndrome; Pneumothorax, primary spontaneous
GPC3 Simpson-Golabi-Behmel syndrome, type 1
HNF1A Renal cell carcinoma
MET Renal cell carcinoma, papillary, 1, familial and somatic
MLH1 Colorectal cancer, hereditary nonpolyposis, type 2;
Mismatch repair cancer syndrome 1;
Muir-Torre syndrome
MSH2 Colorectal cancer, hereditary nonpolyposis, type 1;
Mismatch repair cancer syndrome 2;
Muir-Torre syndrome
MSH6 Colorectal cancer, hereditary nonpolyposis, type 5;
Mismatch repair cancer syndrome 3
PTEN Cowden syndrome 1; Macrocephaly/autism syndrome;
Glioma susceptibility 2; Meningioma
REST Fibromatosis, gingival, 5; Wilms tumor 6, susceptibility to
SDHB Gastrointestinal stromal tumor; Mitochondrial complex II deficiency,
nuclear type 4; Paraganglioma and gastric stromal sarcoma;
Paragangliomas 4; Pheochromocytoma
SDHC Gastrointestinal stromal tumor;
Paraganglioma and gastric stromal sarcoma;
Paragangliomas 3
SDHD Mitochondrial complex II deficiency, nuclear type 3;
Paraganglioma and gastric stromal sarcoma;
Paragangliomas 1, with or without deafness; Pheochromocytoma
SMARCB1 Coffin-Siris syndrome 3; Rhabdoid tumor predisposition syndrome 1;
Schwannomatosis-1, susceptibility to
TP53 Breast cancer; Adrenal cortical carcinoma;
Choroid plexus papilloma;
Colorectal cancer; Li-Fraumeni syndrome;
Nasopharyngeal carcinoma; Osteosarcoma; Pancreatic cancer;
Basal cell carcinoma 7; Glioma susceptibility 1
TSC1 Lymphangioleiomyomatosis; Tuberous sclerosis-1
TSC2 Tuberous sclerosis-2
VHL Erythrocytosis, familial, 2; Pheochromocytoma;
von Hippel-Lindau syndrome
WT1 Denys-Drash syndrome; Frasier syndrome;
Meacham syndrome; Nephrotic syndrome, type 4;
Wilms tumor, type 1

Renal Cancer NGS panel

Published 09/09/2021

Renal Cancer NGS panel

Genes
(full coding
region):		 BAP1, CDC73, CDKN1C, DICER1, DIS3L2, EPCAM, FH, FLCN, GPC3, HNF1A, MET, MLH1, MSH2, MSH6, PTEN, REST, SDHB, SDHC, SDHD, SMARCB1, TP53, TSC1, TSC2, VHL, WT1

List of diseases covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

Severe Combined Immunodeficiency NGS panel

Published 07/07/2021

Severe Combined Immunodeficiency NGS panel

Genes
(full coding
region):		 ADA, AK2, CARD11, CD247, CD40, CD8A, CD3D, CD3E, CD3G, CD40LG, CIITA, CORO1A, DCLRE1C, DOCK8, FOXN1, IKBKB, IL7R, IL2RA, IL2RG, JAK3, LCK, LIG4, MALT1, MTHFD1, NHEJ1, ORAI1, PGM3, PNP, PRKDC, PTPRC, RAC2, RAG1, RAG2, RFX5, RFXANK, RFXAP, RMRP, SLC46A1, STAT5B, STIM1, TBX1, TTC7A, UNC119, ZAP70

List of diseases covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

List of diseases covered by Severe Combined Immunodeficiency NGS panel

Published 07/07/2021

List of diseases covered by
Severe Combined Immunodeficiency NGS panel

Gene Condition
ADA Severe combined immunodeficiency due to ADA deficiency
AK2 Reticular dysgenesis
CARD11 B-cell expansion with NFKB and T-cell anergy; Immunodeficiency 11A;
Immunodeficiency 11B with atopic dermatitis
CD247 Immunodeficiency 25
CD40 Immunodeficiency with hyper-IgM, type 3
CD8A CD8 deficiency, familial
CD3D Immunodeficiency 19
CD3E Immunodeficiency 18, SCID variant
CD3G Immunodeficiency 17, CD3 gamma deficient
CD40LG Immunodeficiency, X-linked, with hyper-IgM
CIITA Bare lymphocyte syndrome, type II, complementation group A;
Rheumatoid arthritis, susceptibility to
CORO1A Immunodeficiency 8
DCLRE1C Severe combined immunodeficiency, Athabascan type; Omenn syndrome
DOCK8 Hyper-IgE recurrent infection syndrome, autosomal recessive
FOXN1 T-cell immunodeficiency, congenital alopecia, and nail dystrophy;
T-cell lymphopenia, infantile, with or without nail dystrophy, autosomal dominant
IKBKB Immunodeficiency 15A; Immunodeficiency 15B
IL7R Severe combined immunodeficiency, T-cell negative,
B-cell/natural killer cell-positive type
IL2RA Immunodeficiency 41 with lymphoproliferation and autoimmunity
IL2RG Combined immunodeficiency, X-linked, moderate;
Severe combined immunodeficiency, X-linked
JAK3 SCID, autosomal recessive, T-negative/B-positive type
LCK Immunodeficiency 22
LIG4 LIG4 syndrome
MALT1 Immunodeficiency 12
MTHFD1 Combined immunodeficiency and megaloblastic anemia
with or without hyperhomocysteinemia
NHEJ1 Severe combined immunodeficiency with microcephaly,
growth retardation, and sensitivity to ionizing radiation
ORAI1 Immunodeficiency 9; Myopathy, tubular aggregate, 2
PGM3 Immunodeficiency 23
PNP Immunodeficiency due to purine nucleoside phosphorylase deficiency
PRKDC Immunodeficiency 26, with or without neurologic abnormalities
PTPRC Severe combined immunodeficiency, T cell-negative,
B-cell/natural killer-cell positive
RAC2 Immunodeficiency 73C with defective neutrophil
chemotaxis and hypogammaglobulinemia;
Immunodeficiency 73A with defective neutrophil chemotaxix and leukocytosis;
Immunodeficiency 73B with defective neutrophil chemotaxis and lymphopenia
RAG1 Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion,
severe cytomegalovirus infection, and autoimmunity; Omenn syndrome;
Combined cellular and humoral immune defects with granulomas;
Severe combined immunodeficiency, B cell-negative
RAG2 Combined cellular and humoral immune defects with granulomas; Omenn syndrome;
Severe combined immunodeficiency, B cell-negative
RFX5 Bare lymphocyte syndrome, type II, complementation group C
RFXANK MHC class II deficiency, complementation group B
RFXAP Bare lymphocyte syndrome, type II,
complementation group D
RMRP Anauxetic dysplasia 1; Cartilage-hair hypoplasia;
Metaphyseal dysplasia without hypotrichosis
SLC46A1 Folate malabsorption, hereditary
STAT5B Growth hormone insensitivity
with immune dysregulation 1, autosomal recessive;
Growth hormone insensitivity with immune dysregulation 2, autosomal dominant
STIM1 Immunodeficiency 10; Myopathy, tubular aggregate, 1;
Stormorken syndrome
TBX1 Conotruncal anomaly face syndrome;
DiGeorge syndrome; Tetralogy of Fallot; Velocardiofacial syndrome
TTC7A Gastrointestinal defects and immunodeficiency syndrome
UNC119 Immunodeficiency 13
ZAP70 Immunodeficiency 48;
Autoimmune disease, multisystem, infantile-onset, 2

Neutropenia NGS panel

Published 30/06/2021

Neutropenia NGS panel

Genes
(full coding
region):		 AP3B1, CSF3R, CXCR4, DNAJC21, EFL1, ELANE, GATA1, GATA2, GFI1, G6PC3, HAX1, JAGN1, LAMTOR2, LYST, RAB27A, RAC2, SBDS, SLC37A4, SMARCD2, SRP54, TAFAZZIN, USB1, VPS13B, VPS45, WAS, WIPF1

List of diseases covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

Malignant Hyperthermia NGS panel

Published 09/04/2021

Malignant Hyperthermia NGS panel

Genes
(full coding
region):		 CACNA1S, RYR1, STAC3
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

Indications for genetic testing:

  1. Clinical episode of malignant hyperthermia (MH)
  2. Positive caffeine/halothane contracture test
  3. Relative with a positive contracture test or a known MH-causing variant
  4. Unexplained death with signs of MH during or immediately after anesthesia
  5. Exercise-related rhabdomyolysis and/or heat stroke

Malignant hyperthermia is an inherited pharmacogenetic disorder of calcium regulation resulting in uncontrolled skeletal muscle hypermetabolism.

Manifestations of MH are triggered by certain volatile anesthetics (i.e. halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with succinylcholine, a depolarizing muscle relaxant. The triggering substances initiate uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate.

MH clinical manifestations are hyperthermia, hypercapnia, tachycardia, acidosis, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure.

In nearly all cases, the first manifestations of MH occur in the operating room, MH may also occur in the early postoperative period. Recent studies show that some individuals with MH will also develop the disorder with exercise and/or on exposure to hot environments. Without prompt treatment with dantrolene sodium, mortality is extremely high.

MH is an autosomal dominant disorder.

References:

Riazi S, Kraeva N, Hopkins PM. Updated guide for the management of malignant hyperthermia. Can J Anaesth. 2018;65:709–21.
Rosenberg H et al. Malignant Hyperthermia Susceptibility. GeneReviews® Initial Posting: December 19, 2003; Last Update: January 16, 2020.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: A review. Orphanet J Rare Dis. 2015;10:93.

Asper Pharmacogenetics

Published 24/03/2021

Asper Pharmacogenetics

Aminoglycoside-Induced Deafness
Antidepressants PGx
Contraceptives + HRT PGx
Malignant Hyperthermia
Statin-Induced Myopathy

Asper Pharmacogenetics is a collection of genetic tests targeting drug-gene interactions including metabolic response to medications and predisposition to adverse drug reactions.

Extensive research has been carried out in the past years to determine the relationship between therapeutic drugs and genes. The studies demonstrate the growing importance of genetically guided treatment, especially in the concept of personalized medicine.

Knowledge on genetic aspects determining drug metabolism allows the implementation of genotype-guided prescription and dosing. It can not only improve drug efficacy but also help prevent adverse drug reactions.

 

CNV analysis

Published 12/02/2021

All NGS panels in our testing menu now include CNV analysis. Panels for frontotemporal dementia, tuberous sclerosis, microcephaly, and hereditary spastic paraplegia cover the analysis of clinically relevant non-coding variants. Learn more at  www.asperbio.com/asper-neurogenetics

List of non-coding variants covered by Microcephaly NGS panel

Published 25/01/2021

List of non-coding variants covered by
Microcephaly NGS panel

Gene Non-coding variant
ASPM c.2761-25A>G
ATR c.6897+464C>G
CDK5RAP2 c.4005-15A>G
CEP152 c.2148-17G>A
DONSON c.786-22A>G
ERCC6 c.1397+7751G>A
EXOSC3 c.475-12A>G
NCAPD3 c.382+14A>G
PNKP c.1387-33_1386+49delCCTCCTCCCCTGACCCC
POMT1 c.-30-2A>G
RBBP8 c.2287+53T>G
XRCC4 c.-10-1G>T

List of non-coding variants covered by Hereditary Spastic Paraplegia NGS panel

Published 22/01/2021

List of non-coding variants covered by
Hereditary Spastic Paraplegia NGS panel

Gene Non-coding variant
BTD c.310-15delT
GBE1 c.2053-3358_2053-3350delGTGTGGTGGinsTGTTTTTTACATGACAGGT
GJC2 c.-170A>G
GJC2 c.-167A>G
GJC2 c.-20+1G>C
L1CAM c.2432-19A>C
L1CAM c.523+12C>T
L1CAM c.2209-42_2229del
PAH c.1199+17G>A
PAH c.1066-11G>A
PAH c.169-13T>G
PLP1 c.454-314T>G
PLP1 c.454-312C>G
PLP1 c.453+159G>A
PLP1 c.453+164G>A
TH c.1198-24T>A
TH c.-70G>A
TH c.-71C>T

List of non-coding variants covered by Microcephaly NGS panel

Published 22/01/2021

List of non-coding variants covered by
Microcephaly NGS panel

Gene Non-coding variant
ASPM c.2761-25A>G
ATR c.6897+464C>G
CDK5RAP2 c.4005-15A>G
CEP152 c.2148-17G>A
DONSON c.786-22A>G
ERCC6 c.1397+7751G>A
EXOSC3 c.475-12A>G
NCAPD3 c.382+14A>G
PNKP c.1387-33_1386+49delCCTCCTCCCCTGACCCC
POMT1 c.-30-2A>G
RBBP8 c.2287+53T>G
XRCC4 c.-10-1G>T

List of diseases covered by Neurofibromatosis NGS panel

Published 20/11/2020

List of diseases covered by
Neurofibromatosis NGS panel

Gene Condition
CCND1 von Hippel-Lindau syndrome, modifier of
LZTR1 Schwannomatosis-2, susceptibility to
NF1 Neurofibromatosis-Noonan syndrome;
Neurofibromatosis, familial spinal; Neurofibromatosis, type 1;
Watson syndrome
NF2 Meningioma, NF2-related, somatic; Neurofibromatosis, type 2;
Schwannomatosis, somatic
SMARCB1 Rhabdoid tumor predisposition syndrome 1;
Schwannomatosis-1, susceptibility to; Coffin-Siris syndrome 3
SPRED1 Legius syndrome
TSC1 Tuberous sclerosis complex
TSC2 Tuberous sclerosis complex
VHL von Hippel-Lindau syndrome

List of diseases covered by Melanoma NGS panel

Published 20/11/2020

List of diseases covered by Melanoma NGS panel

Gene Condition
BAP1 Tumor predisposition syndrome
BRCA2 Fanconi anemia, complementation group D1; Wilms tumor;
Breast cancer, male, susceptibility to;
Breast-ovarian cancer, familial, 2; Glioblastoma 3;
Medulloblastoma; Pancreatic cancer 2; Prostate cancer
CDK4 Melanoma, cutaneous malignant, 3
CDKN2A Melanoma and neural system tumor syndrome;
Melanoma-pancreatic cancer syndrome;
Melanoma, cutaneous malignant, 2
MC1R Melanoma, cutaneous malignant, 5;
Albinism, oculocutaneous, type II, modifier of;
Skin/hair/eye pigmentation 2, blond hair/fair skin
MITF Melanoma, cutaneous malignant, susceptibility to, 8;
Tietz albinism-deafness syndrome
POT1 Melanoma, cutaneous malignant, susceptibility to, 10;
Glioma susceptibility 9
PTEN Cowden syndrome 1; Lhermitte-Duclos syndrome;
Glioma susceptibility 2; Meningioma
RB1 Retinoblastoma
TERT Melanoma, cutaneous malignant, 9;
Dyskeratosis congenita, autosomal dominant 2; Leukemia, acute myeloid;
Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1
XRCC3 Melanoma, cutaneous malignant, 6;
Breast cancer, susceptibility to

List of diseases covered by Frazer Syndrome NGS panel

Published 12/11/2020

List of diseases covered by
Frazer Syndrome NGS panel

Gene Condition
EYA1 Otofaciocervical syndrome;
Anterior segment anomalies with or without cataract; ranchiootic syndrome 1;
Branchiootorenal syndrome 1, with or without cataracts
FREM1 Bifid nose with or without anorectal and renal anomalies;
Manitoba oculotrichoanal syndrome; Trigonocephaly 2
FREM2 Cryptophthalmos, unilateral or bilateral, isolated; Fraser syndrome 2
FRAS1 Fraser syndrome 1
GRIP1 Fraser syndrome 3
SIX1 Branchiootic syndrome 3; Deafness, autosomal dominant 23
SIX5 Branchiootorenal syndrome 2

List of diseases covered by Melanoma NGS panel

Published 09/11/2020

List of diseases covered by Melanoma NGS panel

Gene Condition
BAP1 Tumor predisposition syndrome
BRCA2 Fanconi anemia, complementation group D1; Wilms tumor;
Breast cancer, male, susceptibility to;
Breast-ovarian cancer, familial, 2; Glioblastoma 3;
Medulloblastoma; Pancreatic cancer 2; Prostate cancer
CDK4 Melanoma, cutaneous malignant, 3
CDKN2A Melanoma and neural system tumor syndrome;
Melanoma-pancreatic cancer syndrome;
Melanoma, cutaneous malignant, 2
MC1R Melanoma, cutaneous malignant, 5;
Albinism, oculocutaneous, type II, modifier of;
Skin/hair/eye pigmentation 2, blond hair/fair skin
MITF Melanoma, cutaneous malignant, susceptibility to, 8;
Tietz albinism-deafness syndrome
POT1 Melanoma, cutaneous malignant, susceptibility to, 10;
Glioma susceptibility 9
PTEN Cowden syndrome 1; Lhermitte-Duclos syndrome;
Glioma susceptibility 2; Meningioma
RB1 Retinoblastoma
TERT Melanoma, cutaneous malignant, 9;
Dyskeratosis congenita, autosomal dominant 2; Leukemia, acute myeloid;
Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1
XRCC3 Melanoma, cutaneous malignant, 6;
Breast cancer, susceptibility to

List of non-coding variants covered by Congenital Muscular Dystrophy NGS panel

Published 02/10/2020

List of non-coding variants covered by
Congenital Muscular Dystrophy NGS panel

Gene Non-coding variant
DMD c.9974+175T>A
DMD c.9225-285A>G
DMD c.9225-647A>G
DMD c.8217+18052A>G
DMD c.6614+3310G>T
DMD c.4675-11A>G
DMD c.3432+2036A>G
DMD c.961-5831C>T
DMD c.832-15A>G
DMD c.650-39498A>G
DMD c.265-463A>G
DMD c.93+5590T>A
DMD c.31+36947G>A
FKRP c.-272G>A
FKTN c.648-1243G>T
LAMA2 c.5071+3104del
LMNA c.513+45T>G
LMNA c.1609-12T>G
POMGNT1 1284+2_1284+19del18
POMT1 c.-30-2A>G
SELENON c.*1107T>C

List of diseases covered by Congenital Muscular Dystrophy NGS panel

Published 02/10/2020

List of diseases covered by
Congenital Muscular Dystrophy NGS panel

Gene Condition
B3GALNT2 Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies, type A, 11
B4GAT1 Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 13
CHKB Muscular dystrophy, congenital, megaconial type
COL12A1 Bethlem myopathy 2; Ullrich congenital muscular dystrophy 2
COL6A1 Bethlem myopathy 1; Ullrich congenital muscular dystrophy 1
COL6A2 Bethlem myopathy 1; Myosclerosis, congenital;
Ullrich congenital muscular dystrophy 1
COL6A3 Bethlem myopathy 1; Dystonia 27;
Ullrich congenital muscular dystrophy 1
CRPPA Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7;
Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 7
DAG1 Muscular dystrophy-dystroglycanopathy, type A, 9;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9
DMD Becker muscular dystrophy; Cardiomyopathy, dilated, 3B;
Duchenne muscular dystrophy
DPM1 Congenital disorder of glycosylation, type Ie
DPM2 Congenital disorder of glycosylation, type Iu
DPM3 Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15;
Muscular dystrophy-dystroglycanopathy
(congenital with impaired intellectual development), type B, 15
EMD mery-Dreifuss muscular dystrophy 1, X-linked
FKRP Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 5;
Muscular dystrophy-dystroglycanopathy
(congenital with or without mental retardation), type B, 5;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5
FKTN Muscular dystrophy-dystroglycanopathy, type A, 4;
Muscular dystrophy-dystroglycanopathy, type B, 4;
Muscular dystrophy-dystroglycanopathy
(limb-girdle), type C, 4; Cardiomyopathy, dilated, 1X
GMPPB Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 14;
Muscular dystrophy-dystroglycanopathy
(congenital with mental retardation), type B, 14;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14
ITGA7 Muscular dystrophy, congenital, due to ITGA7 deficiency
LAMA2 Muscular dystrophy, congenital, merosin deficient or partially deficient;
Muscular dystrophy, limb-girdle, autosomal recessive 23
LARGE1 Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 6;
Muscular dystrophy-dystroglycanopathy
(congenital with mental retardation), type B, 6
LMNA Muscular dystrophy, limb-girdle, type 1B;
Charcot-Marie-Tooth disease, type 2B1;
Cardiomyopathy, dilated, 1A;
Emery-Dreifuss muscular dystrophy 2, AD;
Emery-Dreifuss muscular dystrophy 3, AR;
Muscular dystrophy, congenital
POMGNT1 Muscular dystrophy-dystroglycanopathy, type A, 3;
Muscular dystrophy-dystroglycanopathy, type B, 3;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3
POMGNT2 Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies, type A, 8;
Muscular dystrophy-dystroglycanopathy (limb-girdle) type C, 8
POMK Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 12;
Muscular dystrophy-dystroglycanopathy, type A, 12
POMT1 Muscular dystrophy-dystroglycanopathy, type A, 1;
Muscular dystrophy-dystroglycanopathy, type B, 1;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1
POMT2 Muscular dystrophy-dystroglycanopathy, type A, 2;
Muscular dystrophy-dystroglycanopathy, type B, 2;
Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2
RXYLT1 Muscular dystrophy-dystroglycanopathy
(congenital with brain and eye anomalies), type A, 10
SELENON Muscular dystrophy, rigid spine, 1;
Myopathy, congenital, with fiber-type disproportion
TCAP Muscular dystrophy, limb-girdle, type 2G;
Cardiomyopathy, hypertrophic, 25

Congenital Muscular Dystrophy NGS panel

Published 02/10/2020

Congenital Muscular Dystrophy
NGS panel

Genes
(full coding
region):		 B3GALNT2, B4GAT1, CHKB, COL12A1, COL6A1, COL6A2, COL6A3, CRPPA, DAG1, DMD, DPM1, DPM2, DPM3, EMD, FKRP, FKTN, GMPPB, ITGA7, LAMA2, LARGE1, LMNA, POMGNT1, POMGNT2, POMK, POMT1, POMT2, RXYLT1, SELENON, TCAP

List of diseases covered by the panel
Non-coding variants: List of non-coding variants covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

List of diseases covered by Cornelia de Lange Syndrome NGS panel

Published 02/10/2020

List of diseases covered by
Cornelia de Lange Syndrome NGS panel

Gene Condition
AFF4 CHOPS syndrome
ANKRD11 KBG syndrome
HDAC8 Cornelia de Lange syndrome 5
KMT2A Wiedemann-Steiner syndrome
NIPBL Cornelia de Lange syndrome 1
RAD21 Cornelia de Lange syndrome 4
SMC3 Cornelia de Lange syndrome 3
SMC1A Cornelia de Lange syndrome 2
TAF6 Alazami-Yuan syndrome

Cornelia de Lange Syndrome NGS panel

Published 02/10/2020

Cornelia de Lange Syndrome
NGS panel

Genes
(full coding
region):		 AFF4, ANKRD11, HDAC8, KMT2A, NIPBL, RAD21, SMC3, SMC1A, TAF6

List of diseases covered by the panel
Non-coding variants: List of non-coding variants covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

Deletion/duplication analysis of the NIPBL gene

Genes: NIPBL
Lab method: MLPA
TAT: 4-6 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

Indications for genetic testing:

1. Confirmation of clinical diagnosis
2. Carrier testing of at-risk female relatives
3. Prenatal diagnosis for known familial mutation
4. Genetic counseling

Cornelia de Lange syndrome (CdLS) is characterized by distinctive facial features, growth retardation, developmental delay, hirsutism, and limb abnormalities. Craniofacial features include synophrys, arched eyebrows, long eyelashes, small upturned nose and thin downturned lips, small widely spaced teeth, and microcephaly.

Additional findings may include cardiac defects, gastrointestinal dysfunction, hearing loss, myopia, seizures, cleft palate, and cryptorchidism or hypoplastic genitalia.

The prevalence of disorder is estimated at 1:50,000 for the classic form of CdLS. CdLS can be inherited in an autosomal dominant or X-linked manner.

References:

Barisic I et al. EUROCAT Working Group. Descriptive epidemiology of Cornelia de Lange syndrome in Europe. Am J Med Genet A.2008;146A:51–9.
Deardorff MA et al. Cornelia de Lange Syndrome. GeneReviews® 2005 Sept 16 (Updated 2011 Oct 27).
Kline AD et al. Natural history of aging in Cornelia de Lange syndrome. Am J Med Genet C Semin Med Genet. 2007;145C:248–60. 

List of diseases covered by Left Ventricular Noncompaction Cardiomyopathy NGS panel

Published 30/09/2020

List of diseases covered by
Left Ventricular Noncompaction Cardiomyopathy
NGS panel

Gene Condition
ACTC1 Left ventricular noncompaction 4; Cardiomyopathy, hypertrophic, 11;
Atrial septal defect 5
CASQ2 Ventricular tachycardia, catecholaminergic polymorphic, 2
DTNA Left ventricular noncompaction 1, with or without congenital heart defects
FLNC Arrhythmogenic right ventricular dysplasia, familial;
Cardiomyopathy, familial hypertrophic, 26;
Cardiomyopathy, familial restrictive 5;
Myopathy, distal, 4;
Myopathy, myofibrillar, 5
LDB3 Left ventricular noncompaction 3; Myopathy, myofibrillar, 4
LMNA Muscular dystrophy, limb-girdle, type 1B;
Charcot-Marie-Tooth disease, type 2B1;
Cardiomyopathy, dilated, 1A;
Emery-Dreifuss muscular dystrophy 2, AD;
Emery-Dreifuss muscular dystrophy 3, AR;
Muscular dystrophy, congenital; Heart-hand syndrome, Slovenian type;
Lipodystrophy, familial partial, type 2; Malouf syndrome
MIB1 Left ventricular noncompaction 7
MYBPC3 Left ventricular noncompaction 10; Cardiomyopathy, hypertrophic, 4
MYH7 Left ventricular noncompaction 5; Cardiomyopathy, hypertrophic, 1;
Laing distal myopathy; Myopathy, myosin storage, autosomal dominant;
Myopathy, myosin storage, autosomal recessive;
Scapuloperoneal syndrome, myopathic type
PRDM16 Left ventricular noncompaction 8
TAZ Barth syndrome
TNNT2 Left ventricular noncompaction 6; Cardiomyopathy, familial restrictive, 3;
Cardiomyopathy, hypertrophic, 2
TPM1 Left ventricular noncompaction 9; Cardiomyopathy, hypertrophic, 3
VCL Cardiomyopathy, dilated, 1W; Cardiomyopathy, hypertrophic, 15

Left Ventricular Noncompaction Cardiomyopathy NGS panel

Published 30/09/2020

Left Ventricular Noncompaction Cardiomyopathy
NGS panel

Genes
(full
coding region):		 ACTC1, CASQ2, DTNA, FLNC, LDB3, LMNA, MIB1, MYBPC3, MYH7, PRDM16, TAZ, TNNT2, TPM1, VCL

List of diseases covered by the panel
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

 

List of non-coding variants covered by Charcot-Marie-Tooth NGS panel

Published 08/06/2020

List of non-coding variants covered by
Charcot-Marie-Tooth NGS panel

Gene Non-coding variant
CTDP1 c.863+389C>T
GJB1 c.-103C>T
GJB1 c.-17G>A
GJB1 c.-17+1G>T
GJB1 c.-17+2T>C
GJB1 c.-16-2A>G
GJB1 c.-16-1G>A
HK1 c.-390-3838G>C
HK1 c.-390-3818G>C
IGHMBP2 c.1235+894C>A
LMNA c.513+45T>G
LMNA c.1609-12T>G
NTRK1 c.851-33T>A
NTRK1 c.2206-11G>A
SEPT9 c.-134G>C
SURF1 c.324-11T>G

List of non-coding variants covered by Dystonia NGS panel

Published 08/06/2020

List of non-coding variants covered by
Dystonia NGS panel

Gene Non-coding variant
ATM c.2639-384A>G
ATM c.2839-579_2839-576del
ATM c.5763-1050A>G
ATP7B c.-439_-425del
ATP7B c.-676A>G
SLC2A1 c.680-11G>A
TH c.1198-24T>A
TH c.-70G>A
TH c.-71C>T
TIMM8A c.133-23A>C

List of non-coding variants covered by Hereditary Ataxia NGS panel

Published 08/06/2020

List of non-coding variants covered by
Hereditary Ataxia NGS panel

Gene Non-coding variant
ADCK3 c.*72dupG
AMT c.-55C>T
ATM c.-30-1G>T
ATM c.2639-384A>G
ATM c.2839-579_2839-576delAAGT
ATM c.5763-1050A>G
CACNA1A c.631+5G>A
CACNA1A c.4093-3C>G
CACNA1A c.5403+2T>C
CEP290 c.2991+1655A>G
CEP290 c.1910-11T>G
CEP290 c.1066-1G>A
CEP290 c.1190-2A>G
CEP290 c.2052+1_2052+2delGT
CEP290 c.4438-3delC
CEP290 c.4813-2A>G
CEP290 c.3461+1G>A
CEP290 c.6135+2T>A
DARS c.228-22T>A
GSS c.-9+5G>A
KCNJ10 c.-1+1G>T
OFD1 c.935+706A>G
OFD1 c.1130-22_1130-19delAATT
OFD1 c.413-10T>G
PAX6 c.142-14C>G
PAX6 c.-52+5delG
PAX6 c.-52+3_-52+6delAAGTinsTG
PAX6 c.-52+3_-52+4delAA
PAX6 c.-128-2delA
PAX6 c.-129+2T>A
PAX6 c.-129+1G>A
PEX7 c.-45C>T
PNKP c.1386+49_1387_33delCCTCCTCCCCTGACCCC
SERAC1 c.92-165C>T
SERAC1 c.92-239G>C
SLC2A1 c.680-11G>A
SLC52A2 c.-110-1G>A
STUB1 c.*240T>C
SYNE1 c.15918-12A>G
TMEM231 c.824-11T>C
TPP1 c.887-18A>G
TTC19 c.-42G>T

Congenital Fibrosis of Extraocular Muscles NGS panel

Published 11/05/2020

Congenital Fibrosis of Extraocular Muscles NGS panel

Genes
(full coding
region):		 KIF21A, TUBB3, TUBB2B, PHOX2A
Lab method: NGS panel with CNV analysis
TAT: 6-9 weeks
Specimen requirements: 2-4 ml of blood with anticoagulant EDTA

1 µg DNA in TE, AE or pure sterile water at 100-250 ng/µl
The A260/A280 ratio should be 1.8-2.0. DNA sample should be run on an agarose gel as a single band, showing no degradation, alongside with a quantitative DNA marker.
Ordering information: Go to online ordering or download sample submission form

List of diseases covered by Hypomagnesemia NGS panel

Published 17/03/2020

List of diseases covered by
Hypomagnesemia NGS panel

Gene Condition
BSND Bartter syndrome, type 4a
CASR Hyperparathyroidism, neonatal;
Hypocalcemia, autosomal dominant; Hypocalciuric hypercalcemia, type I;
Epilepsy idiopathic generalized, susceptibility to, 8
CLCNKB Bartter syndrome, type 3; Bartter syndrome, type 4b, digenic
CLDN16 Hypomagnesemia 3, renal
CLDN19 Hypomagnesemia 5, renal, with ocular involvement
CNNM2 Hypomagnesemia 6, renal;
Hypomagnesemia, seizures, and mental retardation
CNNM4 Jalili syndrome
EGF Hypomagnesemia 4, renal
FAM111A Kenny-Caffey syndrome, type 2;
Gracile bone dysplasia
FXYD2 Hypomagnesemia 2, renal
HNF1B Renal cysts and diabetes syndrome;
Diabetes mellitus, noninsulin-dependent; Renal cell carcinoma
KCNA1 Episodic ataxia/myokymia syndrome
KCNJ10 Enlarged vestibular aqueduct, digenic;
SESAME syndrome
MAGT1 Congenital disorder of glycosylation, type Icc;
Immunodeficiency, X-linked, with magnesium defect,
Epstein-Barr virus infection and neoplasia
PCBD1 Hyperphenylalaninemia, BH4-deficient, D
SARS2 Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis
SLC12A3 Gitelman syndrome
TRPM6 Hypomagnesemia 1, intestinal